Proton pump inhibitor therapy does not affect hydrogen production on lactulose breath test in subjects with IBS

Digestive Diseases and Sciences

Volumn 55, Issue 8, 2010, Pages 2302-2308

  Law, David ^a   Pimentel, Mark ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

IBS; Lactulose breath test; Proton pump inhibitor

Indexed keywords

HYDROGEN; METHANE; PROTON PUMP INHIBITOR;

ADULT; ARTICLE; BACTERIAL OVERGROWTH; BREATH ANALYSIS; CONTROLLED STUDY; DRUG EFFECT; DRUG USE; FEMALE; HUMAN; IRRITABLE COLON; LACTULOSE BREATH TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUESTIONNAIRE;

ADULT; BREATH TESTS; FEMALE; HUMANS; HYDROGEN; IRRITABLE BOWEL SYNDROME; LACTULOSE; MALE; MIDDLE AGED; PROTON PUMP INHIBITORS; RETROSPECTIVE STUDIES;

EID: 77954428040     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-009-1010-2     Document Type: Article

References (34)

1. G Bommelaer T Poynard C Le Pen AF Gaudin F Maurel G Priol et al. 2004 Prevalence of irritable bowel syndrome (IBS) and variability of diagnostic criteria Gastroenterol Clin Biol 28 554 561 10.1016/S0399-8320(04)95011-7 15243388 (Pubitemid 38917487)
2. S Wilson L Roberts A Roalfe P Bridge S Singh 2004 Prevalence of irritable bowel syndrome: a community survey Br J Gen Pract 54 495 502 15239910 (Pubitemid 38931344)
3. KA Gwee S Wee ML Wong DJ Png 2004 The prevalence, symptom characteristics, and impact of irritable bowel syndrome in an Asian urban community Am J Gastroenterol 99 924 931 10.1111/j.1572-0241.2004.04161.x 15128362 (Pubitemid 39090225)
4. HB El-Serag 2003 Impact of irritable bowel syndrome: prevalence and effect on health-related quality of life Rev Gastroenterol Disord 3 Suppl 2 S3 S11 12775997
5. AP Hungin PJ Whorwell J Tack F Mearin 2003 The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects Ailment Pharmacol Ther 17 643 650 10.1046/j.1365-2036.2003.01456.x 1:STN:280:DC%2BD3s7islCntg%3D%3D (Pubitemid 36418887)
6. L Agreus K Svardsudd O Nyren G Tibblin 1995 Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time Gastroenterology 109 671 680 10.1016/0016-5085(95)90373-9 1:STN:280: DyaK2MzosF2hsQ%3D%3D 7657095
7. Drossman DA, Richter JE, Talley NJ et al. (eds) Functional gastrointestinal disorders: diagnosis, pathophysiology and treatment: a multinational consensus. Boston: Little Brown, 1994.
8. M Pimentel EJ Chow HC Lin 2000 Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome Am J Gastroenterol 95 3503 3506 10.1111/j.1572-0241.2000.03368.x 1:STN:280:DC%2BD3M%2FpvFSmtA%3D%3D 11151884
9. M Pimentel EJ Chow HC Lin 2003 Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: a double-blind, randomized, placebo-controlled study Am J Gastroenterol 98 412 419 12591062 (Pubitemid 36232393)
10. A Lupascu M Gabrielli EC Lauritano et al. 2005 Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome Aliment Pharmacol Ther 22 1157 1160 10.1111/j.1365-2036.2005.02690.x 1:STN:280:DC%2BD2MnisVKntA%3D%3D 16305730 (Pubitemid 41779524)
11. M Grover M Kanazawa OS Palsson et al. 2008 Small intestinal bacterial overgrowth in irritable bowel syndrome: association with colon motility, bowel symptoms, psychological distress Neurogastroenterol Motil 20 9 998 1008 10.1111/j.1365-2982.2008.01142.x 1:STN:280:DC%2BD1crivFGhtA%3D%3D 18482250
12. R McCallum C Schultz S Sostarich 2005 Evaluating the role of small intestinal bacterial overgrowth (SIBO) in diarrhea predominant irritable bowel syndrome (IBS-D) patients utilizing the glucose breath test (GBT) Gastroenterol 128 A460
13. M Pimentel S Park J Mirocha et al. 2006 The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial Ann Intern Med 145 557 563 17043337 (Pubitemid 46780934)
14. Shahara Al E Aoun H Abdul-Baki R Mounzer S Sidani I ElHajj 2006 A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence Am J Gastroenterol 101 326 333 10.1111/j.1572-0241.2006.00458.x (Pubitemid 43381675)
15. Lembo A, Zakko S, Ferreira N et al. Rifaximin for the treatment of diarrhea-associated irritable bowel syndrome: short term treatment leading to long term sustained response. Gastroenterology. 2008;134:A-545.
16. I Nastaskin E Mehdikhani J Conklin et al. 2006 Studying the overlap between IBS and GERD: a systematic review of the literature Dig Dis Sci 51 2113 2120 10.1007/s10620-006-9306-y 17080246
17. I Posserud PO Stotzer ES Bjornsson H Abrahamsson M Simren 2007 Small intestinal bacterial overgrowth in patients with irritable bowel syndrome Gut 56 6 802 808 10.1136/gut.2006.108712 17148502 (Pubitemid 46854194)
18. BMR Spiegel WD Chey L Chang 2006 Bacterial overgrowth and irritable bowel syndrome: unifying hypothesis or a spurious consequence of proton pump inhibitors? Am J Gastroenterol 103 2972 2976 10.1111/j.1572-0241.2008.01992.x
19. R Khoshini SC Dai S Lezcano M Pimentel 2008 A systematic review of diagnostic tests for small intestinal bacterial overgrowth Dig Dis Sci 53 1443 1454 10.1007/s10620-007-0065-1 17990113
20. A Riedl M Schmidtmann A Stengel M Goebel AS Wisser BF Klapp H Monnikes 2008 Somatic comorbidities of IBS: a systematic analysis J Psychosom Res 64 6 573 582 10.1016/j.jpsychores.2008.02.021 18501257
21. C Williams KEL McColl 2006 Review article: proton pump inhibitors and bacterial overgrowth Aliment Pharmacol Ther 23 3 10 10.1111/j.1365-2036.2006. 02707.x 1:STN:280:DC%2BD28%2FgslShtQ%3D%3D 16393275 (Pubitemid 43381161)
22. J Theisen D Nehra D Citron et al. 2000 Suppression of gastric acid secretion in patients with gastroesophageal reflux disease results in gastric bacterial overgrowth and deconjugation of bile acids J Gastrointest Surg 4 50 54 10.1016/S1091-255X(00)80032-3 1:STN:280:DC%2BD3c%2FpvVyktw%3D%3D 10631362
23. SJ Lewis S Franco G Young SJD O'Keefe 1996 Altered bowel function and duodenal bacterial overgrowth in patients treated with omeprazole Aliment Pharm Ther 10 557 561 10.1046/j.1365-2036.1996.d01-506.x 1:CAS:528:DyaK28XltlaisbY%3D (Pubitemid 26254799)
24. SP Pereira N Gainsborough RH Dowling 1998 Drug-induced hypochlorhydria causes high duodenal bacterial counts in the elderly Aliment Pharmacol Ther 12 99 104 10.1046/j.1365-2036.1998.00275.x 1:STN:280:DyaK1czlsFCmtA%3D%3D 9692707 (Pubitemid 28057411)
25. M Fried H Siegrist R Frei et al. 1994 Duodenal bacterial overgrowth during treatment in outpatients with omeprazole Gut 35 23 26 10.1136/gut.35.1.23 1:STN:280:DyaK2c7ktVajtQ%3D%3D 8307444 (Pubitemid 24059466)
26. M Pimentel AG Mayer S Park et al. 2003 Methane production during lactulose breath test is associated with gastrointestinal disease presentation Dig Dis Sci 48 86 92 10.1023/A:1021738515885 12645795 (Pubitemid 36232767)
27. M Pimentel HC Lin P Enayati et al. 2006 Methane, a gas produced by enteric bacteria, slows intestinal transit and augments ileal contractile activity Am J Physiol Gastrointest Liver Physiol 290 G1089 G1095 10.1152/ajpgi.00574.2004 1:CAS:528:DC%2BD28XlvVeis7w%3D 16293652 (Pubitemid 43788289)
28. GR Locke 3rd AR Zinsmeister SL Fett et al. 2005 Overlap of gastrointestinal symptom complexes in a US community Neurogastroenterol Motil 14 29 34 10.1111/j.1365-2982.2004.00581.x (Pubitemid 40204009)
29. J Thorens F Froehlich W Schwizer et al. 1996 Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomized double blind study Gut 39 54 59 10.1136/gut.39.1.54 1:CAS:528:DyaK28XkvFertrc%3D 8881809 (Pubitemid 26239105)
30. E Rubinstein Z Mark J Haspel et al. 1985 Antibacterial activity of the pancreatic fluid Gastroenterol 88 927 932 1:STN:280:DyaL2M7ivVeiug%3D%3D (Pubitemid 15105883)
31. R Fass M Shapiro R Dekel J Sewell 2005 Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease - where next? Aliment Pharmacol Ther 22 79 94 10.1111/j.1365-2036.2005.02531.x 1:CAS:528: DC%2BD2MXpt1Cjt70%3D 16011666 (Pubitemid 41568545)
32. KR Neal HM Scott RCB Slack RFA Logan 1996 Omeprazole as a risk factor for Campylobacter gastroenteritis: case-control study BMJ 312 414 415 1:STN:280:DyaK287nsFWitA%3D%3D 8601113 (Pubitemid 26055357)
33. S Dial K Alrasadi C Manoukian A Huang D Menzies 2004 Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies Can Med Assoc J 6 33 38 10.1503/cmaj.1040876 (Pubitemid 38925116)
34. R Cunningham B Dale B Undy N Gaunt 2003 Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea J Hosp Infect 54 243 245 10.1016/S0195-6701(03)00088-4 1:STN:280:DC%2BD3szis1Sqsw%3D%3D 12855243 (Pubitemid 38002001)